The Court of Justice of the European Union Clarifies When Human Embryonic Stem Cells Can Be Patented

Bonadio, E. & Rovati, A. M. (2015). The Court of Justice of the European Union Clarifies When Human Embryonic Stem Cells Can Be Patented. European Journal of Risk Regulation, 5(2), pp. 293-295.

[img]
Preview
Text - Accepted Version
Download (249kB) | Preview

Abstract

On 18 December 2014, in International Stem Cell Corporation v. Comptroller General of Patents, Designs and Trade Marks (C-364/13), the Court of Justice of the European Union (CJEU) delivered an important decision regarding the scope of the exclusion from patentability on morality-related grounds under Article 6(2) of the EU Biotech Directive. The Court made an important distinction between embryonic stem cell technologies based on fertilised human ovum and those based on unfertilised human ovum stimulated by parthenogenesis. The CJEU held, in particular, that a human ovum: (i) who is unfertilized and (ii) whose division and further development has been stimulated by parthenogenesis, is not a human embryo under Article 6(2)(c) of the Biotech Directive, if it in itself has not the inherent capacity of developing into a human being, this matter to be ascertained by the national court in the light of current scientific knowledge. By doing so, the Court clarified its previous ruling in Brüstle (October 2011).

Item Type: Article
Subjects: K Law
Divisions: The City Law School > The City Law School - Academic Programmes
URI: http://openaccess.city.ac.uk/id/eprint/12129

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics